Sandoz Is Satisfied With US Pegfilgrastim Start

Promising Initial Signs For Ziextenzo

 
• By Aidan Fry

Initial market signals from Sandoz’ US launch of its Ziextenzo pegfilgrastim biosimilar are promising, global Biopharmaceuticals head Pierre Bourdage told Generics Bulletin.

Good start
Sandoz says its Ziextenzo pegfilgrastim biosimilar is off to a good start in the US • Source: Shutterstock

More from Biosimilars

More from Products